Format

Send to

Choose Destination
Skin Therapy Lett. 2015 Sep-Oct;20(5):1-6.

Apremilast in the treatment of psoriasis and psoriatic arthritis.

Author information

1
Skin Centre for Dermatology, Peterborough, ON, Canada; Probity Medical Research, Waterloo, ON, Canada.
2
K. Papp Clinical Research, Waterloo, ON, Canada; Probity Medical Research, Waterloo, ON, Canada.

Abstract

Phosphodiesterase 4 (PDE4) is a key enzyme in the regulation of immune responses of inflammatory diseases through degradation of the second messenger, cyclic adenosine 3',5'-monophosphate (cAMP). Apremilast, a selective PDE4 inhibitor, has been shown to reduce the production of pro-inflammatory cytokines by increasing intracellular levels of cAMP and promoting the production of anti-inflammatory cytokines. The efficacy and safety of apremilast in the treatment of psoriasis and psoriatic arthritis has been demonstrated in phase 2 and 3 studies and will be reviewed here. Across all studies, treatment was generally well-tolerated with some mild gastrointestinal complaints that occurred early and resolved over time, resulting in few drop-outs. Meaningful changes in dactylitis and enthesitis were also observed. Routine monitoring is not required given the absence of drug associated physiologic, biochemical, and haematological changes. Apremilast proves to be a new promising systemic therapy for treating psoriatic disease.

PMID:
26382906
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Skin Therapy Letter
Loading ...
Support Center